BRPI0414927A - antagonistas de integrina alfavbeta3 e alfavbeta6 como agentes antifibróticos - Google Patents

antagonistas de integrina alfavbeta3 e alfavbeta6 como agentes antifibróticos

Info

Publication number
BRPI0414927A
BRPI0414927A BRPI0414927-0A BRPI0414927A BRPI0414927A BR PI0414927 A BRPI0414927 A BR PI0414927A BR PI0414927 A BRPI0414927 A BR PI0414927A BR PI0414927 A BRPI0414927 A BR PI0414927A
Authority
BR
Brazil
Prior art keywords
antagonists
fibrosis
alfavbeta6
agents
integrins
Prior art date
Application number
BRPI0414927-0A
Other languages
English (en)
Inventor
Simon Goodman
Detlef Schuppan
Eleonora Patsenker
Yury Popov
Michael Bauer
Matthias Wiesner
Alfred Jonczyk
Original Assignee
Merck Patent Ges Mit Beschaenk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschaenk filed Critical Merck Patent Ges Mit Beschaenk
Publication of BRPI0414927A publication Critical patent/BRPI0414927A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"ANTAGONISTAS DE INTEGRINA ALFAVBETA3 E ALFAVBETA6 COMO AGENTES ANTIFIBRóTICOS". Esta invenção refere-se à inibição de ap integrinas, especialmente a<244>v<225>3 e <244>v<225>6 integrinas, por antagonistas específicos, de preferência antagonistas não-peptídicos, compostos correlatos e compostos com especificidade comparável, que regulam para baixo a fibrogênese através da inibição de migração de célula e produção de moléculas pró-fibrogênicas (por exemplo, colágenos, TIMP-1) e citoquinas (por exemplo, CTGF) de células /miofibroblastos estrelados hepáticos ativados, epitélios ativados e endotélios. Esses antagonistas sozinhos ou em combinação com outros agentes podem evitar eficazmente, mitigar ou mesmo reverter o desenvolvimento de fibrose avançada, tal como fibrose/cirrose do fígado e fibrose de outros órgãos, tais como pulmões, rins, intestinos, pâncreas, pele e artérias.
BRPI0414927-0A 2003-10-01 2004-09-16 antagonistas de integrina alfavbeta3 e alfavbeta6 como agentes antifibróticos BRPI0414927A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03022048 2003-10-01
PCT/EP2004/010396 WO2005039547A1 (en) 2003-10-01 2004-09-16 Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents

Publications (1)

Publication Number Publication Date
BRPI0414927A true BRPI0414927A (pt) 2006-11-07

Family

ID=34486055

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414927-0A BRPI0414927A (pt) 2003-10-01 2004-09-16 antagonistas de integrina alfavbeta3 e alfavbeta6 como agentes antifibróticos

Country Status (18)

Country Link
US (1) US20070117849A1 (pt)
EP (1) EP1667668B1 (pt)
JP (1) JP4912881B2 (pt)
KR (1) KR101191068B1 (pt)
CN (1) CN100462068C (pt)
AR (1) AR045960A1 (pt)
AT (1) ATE399542T1 (pt)
AU (1) AU2004283413B2 (pt)
BR (1) BRPI0414927A (pt)
CA (1) CA2540730C (pt)
DE (1) DE602004014795D1 (pt)
DK (1) DK1667668T3 (pt)
ES (1) ES2308227T3 (pt)
MX (1) MXPA06003477A (pt)
PL (1) PL1667668T3 (pt)
RU (1) RU2388472C2 (pt)
WO (1) WO2005039547A1 (pt)
ZA (1) ZA200603427B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646160A (zh) 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
CN101497656B (zh) * 2009-03-09 2012-08-15 东南大学 与整合素αvβ3具有高结合活性的多肽及其应用
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
ES2875535T3 (es) * 2012-03-29 2021-11-10 Biogen Ma Inc Biomarcadores para su uso en aplicaciones de terapia de integrina
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
US9085606B2 (en) 2012-07-18 2015-07-21 Saint Louis University Beta amino acid derivatives as integrin antagonists
WO2014124302A1 (en) 2013-02-07 2014-08-14 Scifluor Life Sciences, Llc Fluorinated integrin antagonists
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2016134223A2 (en) * 2015-02-19 2016-08-25 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
AU2016381336A1 (en) 2015-12-30 2018-06-28 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
ES2898835T3 (es) * 2016-11-08 2022-03-09 Bristol Myers Squibb Co Azol amidas y aminas como inhibidores de la integrina alfav
AU2017359030A1 (en) * 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Pyrrole amides as alpha v integrin inhibitors
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
KR20190095936A (ko) 2016-12-14 2019-08-16 프로제너티, 인크. 인테그린 저해제로의 위장관 질환의 치료
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN120960406A (zh) * 2024-05-16 2025-11-18 浙江大学 靶向整合素αVβ6的CAR-免疫细胞在预防和/或治疗纤维化疾病中的应用
CN118641765B (zh) * 2024-05-17 2025-06-20 中国医学科学院医药生物技术研究所 Tinagl1在制备抗肝纤维化药物中的应用及化合物的新用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
BR0008310A (pt) * 1999-02-20 2002-01-22 Merck Patent Gmbh Derivados de alfa-alanina
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
DE10063173A1 (de) * 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
AU2002306651B2 (en) * 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
DE10112771A1 (de) * 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
ES2243744T3 (es) * 2001-08-01 2005-12-01 Merck Patent Gmbh Inhibidores de integrina para el tratamiento de enfermedades de los ojos.
WO2003068253A1 (en) * 2002-02-14 2003-08-21 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases

Also Published As

Publication number Publication date
CA2540730A1 (en) 2005-05-06
JP4912881B2 (ja) 2012-04-11
AR045960A1 (es) 2005-11-16
EP1667668B1 (en) 2008-07-02
KR20060090818A (ko) 2006-08-16
KR101191068B1 (ko) 2012-10-15
WO2005039547A1 (en) 2005-05-06
JP2007507440A (ja) 2007-03-29
RU2006114395A (ru) 2007-11-27
CN100462068C (zh) 2009-02-18
PL1667668T3 (pl) 2008-10-31
AU2004283413A1 (en) 2005-05-06
RU2388472C2 (ru) 2010-05-10
ATE399542T1 (de) 2008-07-15
DE602004014795D1 (de) 2008-08-14
DK1667668T3 (da) 2008-09-15
US20070117849A1 (en) 2007-05-24
ZA200603427B (en) 2007-09-26
AU2004283413B2 (en) 2010-09-02
EP1667668A1 (en) 2006-06-14
ES2308227T3 (es) 2008-12-01
MXPA06003477A (es) 2006-06-05
CA2540730C (en) 2012-08-21
CN1863520A (zh) 2006-11-15

Similar Documents

Publication Publication Date Title
ID29534A (id) Turunan-turunan asam pirazolkarboksilat, pembuatannya, komposisi-komposisi farmasi yang mengandungnya
DE60138403D1 (de) Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
MXPA03001511A (es) Imidazol-5-il-2-amino-pirimidinas como agentes para la inhibicion de la proliferacion celular.
DE60144032D1 (de) Galvanisch abgeschiedener verbundfilm und verfahren zu seiner herstellung
EP1665358A4 (en) Fabrication of single or multiple gate field plates
NO20004027L (no) Fluorinerte ionomerer og deres anvendelser
BRPI0407373A (pt) Espuma hidro-alcoólica formando espuma em filme
NO20042263L (no) System ved lagring i vann av sement for avstandstykke samt fremgangsmate og anvendelse av samme
BRPI0409093B1 (pt) método de preparação de um eletrólito baseado em céria com uma densidade maior do que 97% da densidade teórica alcançável, eletrólito baseado em céria, e, montagem de meia-célula
AR066527A1 (es) Panel para la contruccion de edificios con salientes perpendiculares a una cara
DE602004026522D1 (de) Target für Elektronstrahlverdampfung und Verfahren zur dessen Herstellung.
DE60302610D1 (de) Ionenaustauschermembran-Elektrolyseur
AR045960A1 (es) Uso terapeutico de antagonistas de alfa v beta 3 y alfa v beta 6 integrinas como agentes antifibroticos
WO2003010336A3 (de) Molekulare marker beim hepatozellulären karzinom
PT1553942E (pt) Composicao farmaceutica associando tenatoprazol e um anti-inflamatorio
ITTO980997A0 (it) Prodotto verniciante in fase acquosa, suo procedimento di produzione e corredo impiegabile in tale procedimento.
DK1712696T3 (da) Kerneisoleret præfabrikeret væg med forbindelsesnåle
ITMI20030985A1 (it) Elemento costruttivo composito, in particolare per la realizzazione di strutture di parete per edifici e procedimento per la sua fabbricazione.
AU313308S (en) Bowl
ITMI20022384A1 (it) Sanitari da bagno in legno e procedimento per la loro produzione.
ATE409191T1 (de) 1,3-diaza-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
DK1490216T3 (da) Fremstilling af kompositelementer
DE10081707T1 (de) Verfahren zur Herstellung von Stahlblech für Schattenmasken mit ausgezeichneter Dickengenauigkeit in Längsrichtung
DE50003587D1 (de) Verbundelemente
ATE374947T1 (de) Bestimmung freier fraktionen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.5 NA RPI NO 2494 DE 23/10/2018 POR TER SIDO INDEVIDA.

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2437 DE 19/09/2017 POR TER SIDO INDEVIDA, UMA VEZ QUE O PEDIDO FOI ARQUIVADO (DESPACHO 11.5, SEM PETICIONAMENTO DE RECURSO ADMINISTRATIVO) EM 18/04/2017

B11T Dismissal of application maintained [chapter 11.20 patent gazette]